The NIBR Biologics Center (NBC) focuses on the discovery of biologics, primarily antibodies and protein drugs, and is responsible for generating new biotherapeutics within NIBR. As a class of medicine, biologics are a powerful tool that can often treat diseases that cannot be treated with traditional approaches.

Antibody and protein drugs are produced using recombinant DNA technology. Therapeutic antibodies are similar to those made by the human immune system, but are designed in the laboratory to specifically bind to disease targets in the body.

Therapeutic proteins are often similar or identical to naturally occurring proteins in the body, but they are used to replace, augment, or inhibit some function related to diseases. In NBC, a wide range of modern technologies are developed and applied to discover, optimize and modify proteins for biotherapeutic use in all NIBR disease areas.


Selected publications

Interaction with both ZNRF3 and LGR4 is required for the signaling activity of R-spondin. Xie Y, Zamponi R, Charlat O, Ramones M, Swalley S, Jiang X, Rivera D, Tschantz W, Lu B, Quinn L, Dimitri C, Parker J, Jeffery D, Wilcox SK, Watrobka M, LeMotte P, Granda B, Porter JA, Myer VE, Loew A, Cong F. EMBO Rep. 2013 Dec;14(12):1120-6. doi: 10.1038/embor.2013.167. Epub 2013 Oct 29.

Transient Recombinant Protein Expression in a Human Amniocyte Cell Line: The CAP-T® Cell System. S.Fischer, N.Charara, A.Gerber, J.Wölfel, G.Schiedner, B.Voedisch, S.Geisse: Biotechnol. Bioeng. 109(9):2250-2261, 2012.

TEM8/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types.Chaudhary A. Hilton MB. Seaman S. Haines DC. Stevenson S. Lemotte PK. Tschantz WR. Zhang XM. Saha S. Fleming T. St Croix B. Cancer Cell. 21(2):212-26, 2012.